LDLoren C. Denlinger

Loren C. Denlinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Loren C. Denlinger has a total of 218 co-authors. Here are the top co-authors by number of shared publications:

  • Nizar N. Jarjour

    Division of Allergy, Pulmonary and Critical Care Medicine

    5 shared publications
  • Mario Castro

    University of Kansas School of Medicine

    4 shared publications
  • Nizar N. Jarjour

    Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health , Madison, WI

    4 shared publications
  • Stephane Esnault

    Université de Lille, Inserm, Centre Hospitalier Universitaire (CHU) Lille, U1286, Institute for Translational Research in Inflammation , Lille F-59000

    4 shared publications
  • David M. Manthei

    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

    3 shared publications
  • Mats W. Johansson

    Division of Allergy, Pulmonary and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health , 600 Highland Avenue, Madison, WI 53792

    3 shared publications

Latest Publications

  • PrecISE—a biomarker-stratified adaptive trial of 5 interventions in severe asthma: Final protocol and the baseline cohort

    by Loren C Denlinger, Elliot Israel, Wendy C Moore, Steve N Georas, Rosalind J Wright, Mario Castro, David B Peden, Kevin J Anstrom, Eugene R Bleecker, Laura Crotty Alexander, et al.


  • Association between absolute blood eosinophil count and carotid plaque and coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA)

    by Nyla E Mathis, Mats W Johansson, Spencer L Hansen, Alison S Dasiewicz, Stephane Esnault, Sameer K Mathur, Loren C Denlinger, Robyn L McClelland, Nizar N Jarjour, James H Stein, et al.

    Prior studies have demonstrated associations between eosinophil activation products and incident stroke. We investigated whether circulating eosinophil concentration is associated with imaging markers of atherosclerotic cardiovascular disease (ASCVD), analyzing 2 arterial beds (carotid artery plaque [CAP] and coronary artery calcium [CAC]) in the Multi-Ethnic Study of Atherosclerosis (MESA). The MESA enrolled individuals aged 45 to 84, without ASCVD at baseline. ASCVD risk factors, blood eosinophils, CAP presence/score (0 to 12), and CAC presence/Agatston score were measured at MESA Exam No. 5. Using logistic and linear regression analyses, the relationships between blood eosinophils, CAP or CAC presence, or scores (log[score + 1]), adjusted for confounders, were evaluated. The 2,166 participants were a mean (standard deviation [SD]) 69.6 (9.3) years old, 53% female, 29% Hispanic, 28% Black, 1% Chinese American. The eosinophil count was median (interquartile range) 0.10 (0.10, 0.20)×103/μl, CAP score 2 (0, 4), and CAC score 45 (0, 292) Agatston units. In risk-factor adjusted models, increased blood eosinophil count (per 1 SD [0.15 × 103/μl]) was associated with log scores of CAP (β: 0.05 [95% confidence interval 0.02 to 0.08, P = 0.001) or CAC (β: 0.11, [0.01 to 0.21], P = 0.03). Similar associations were observed for eosinophils and CAP (odds ratio [OR]: 1.12, [1.01 to 1.25], P = 0.03) and CAC (OR: 1.15, [1.02 to 1.30], P = 0.02) presence. In conclusion, in a large, multiethnic US cohort, blood eosinophils were independently linked to imaging atherosclerosis measures in 2 arterial distributions. These data suggest potential roles of eosinophilic inflammation in atherosclerosis.


  • Proteomic Analysis of Asthma Airway Inflammation after Allergen Challenge: A Heterogeneous Response

    by Mats W. Johansson, Stephane Esnault, Robert J. Millikin, John W. Steill, Kristine E. Lee, Heather L. Floerke, Loren C. Denlinger, Ron Stewart, Nizar N. Jarjour, Matthew C. Tattersall


  • Open Access

    A method for MRI‐guided bronchoscopy to identify obstructed airway segments

    by David G. Mummy, Marrissa J. McIntosh, Katherine J. Carey, Shannon Kehoe, Stephane Esnault, Mats W. Johansson, Michael D. Evans, Ronald L. Sorkness, Mark Schiebler, Nizar N. Jarjour, et al.

    Bronchoscopy is not conventionally guided by prior knowledge of segmental airway obstruction. Hyperpolarized gas magnetic resonance imaging (MRI) ventilation abnormalities and computed tomography (CT) air trapping are related to lung function and asthma severity but have not been used to target segmental inflammation and remodeling. We evaluate the feasibility of using bronchoscopy guided by 3He MRI and CT to reveal differences in inflammatory response, morphology, and cellular activity in poorly‐ (defect) versus well‐ventilated (control) lung regions. Eleven participants (5 female; age, 22.8 ± 3.4 years; 9 asthma) who experienced a cold with increased lower airway symptoms underwent 3He MRI and/or CT at least 6 weeks after recovery. Differences between defect and control regions were compared. In defect as compared to control sites, bronchoalveolar lavage neutrophils (p = 0.06) and granulocytes (p = 0.08) trended towards an increase; inflammatory mediators (i.e., 15‐epi‐LXA4, LXA4) were also significantly different (p < 0.05) between sites. Correlations were observed between macrophages, neutrophils, and eosinophils with inflammatory mediators (i.e., 15‐epi‐LXA4, LXA4, LTB4). Correlations were observed for macrophages and neutrophils with 15‐epi‐LXA4, and eosinophils with LXA4 and leukotriene B4. Basement membrane wall thickness was similar for defect versus control sites (p = 0.9). These results support the feasibility of image‐guided methods to identify airway obstruction phenotypes.


  • Eosinophil-Epithelial Cell Interactions in Asthma

    by Breanne N. Steffan, Elizabeth A. Townsend, Loren C. Denlinger, Mats W. Johansson

    Background: Eosinophils have numerous roles in type 2 inflammation depending on their activation states in the blood and airway or after encounter with inflammatory mediators. Airway epithelial cells have a sentinel role in the lung and, by instructing eosinophils, likely have a foundational role in asthma pathogenesis. Summary: In this review, we discuss various topics related to eosinophil-epithelial cell interactions in asthma, including the influence of eosinophils and eosinophil products, e.g., granule proteins, on epithelial cell function, expression, secretion, and plasticity; the effects of epithelial released factors, including oxylipins, cytokines, and other mediators on eosinophils, e.g., on their activation, expression, and survival; possible mechanisms of eosinophil-epithelial cell adhesion; and the role of intra-epithelial eosinophils in asthma. Key Messages: We suggest that eosinophils and their products can have both injurious and beneficial effects on airway epithelial cells in asthma and that there are bidirectional interactions and signaling between eosinophils and airway epithelial cells in asthma.


  • Open Access

    Comparison of Asthma Phenotypes in Severe Asthma Cohorts (SARP, U-BIOPRED, ProAR and COREA) From 4 Continents

    by So-Young Park, Stephen Fowler, Dominic E. Shaw, Ian M. Adcock, Ana R. Sousa, Ratko Djukanovic, Sven-Erik Dahlen, Peter J. Sterk, Nazanin Zounemat Kermani, William Calhoun, et al.

    Park SY, et al. Allergy Asthma Immunol Res. 2024 Jul;16(4):338-352. https://doi.org/10.4168/aair.2024.16.4.338


  • Imaging Regional Airway Involvement of Asthma: Heterogeneity in Ventilation, Mucus Plugs and Remodeling

    by Mark L. Schiebler, Nanae Tsuchiya, Andrew Hahn, Sean Fain, Loren Denlinger, Nizar Jarjour, Eric A. Hoffman

    The imaging of asthma using chest computed tomography (CT) is well-established (Jarjour et al., Am J Respir Crit Care Med 185(4):356–62, 2012; Castro et al., J Allergy Clin Immunol 128:467–78, 2011). Moreover, recent advances in functional imaging of the lungs with advanced computer analysis of both CT and magnetic resonance images (MRI) of the lungs have begun to play a role in quantifying regional obstruction. Specifically, quantitative measurements of the airways for bronchial wall thickening, luminal narrowing and distortion, the amount of mucus plugging, parenchymal density, and ventilation defects that could contribute to the patient’s disease course are instructive for the entire care team. In this chapter, we will review common imaging methods and findings that relate to the heterogeneity of asthma. This information can help to guide treatment decisions. We will discuss mucous plugging, quantitative assessment of bronchial wall thickening, delta lumen phenomenon, parenchymal low-density lung on CT, and ventilation defect percentage on MRI as metrics for assessing regional ventilatory dysfunction. Keywords Computed tomography Small airways disease Hyper Polarized Disease probability measure Airway network flow model Magnetic resonance imaging Regional airflow Mucus plugs Remodeling


  • Clinical Trial Design Innovations for Precision Medicine in Asthma

    by Salman Siddiqui, Elin Haf Davies, Majid Afshar, Loren C. Denlinger

    Severe asthma is a spectrum disorder with numerous subsets, many of which are defined by clinical history and a general predisposition for T2 inflammation. Most of the approved therapies for severe asthma have required clinical trial designs with population enrichment for exacerbation frequency and/or elevation of blood eosinophils. Moving beyond this framework will require trial designs that increase efficiency for studying nondominant subsets and continue to improve upon biomarker signatures. In addition to reviewing the current literature on biomarker-informed trials for severe asthma, this chapter will also review the advantages of master protocols and adaptive design methods for establishing the efficacy of new interventions in prospectively defined subsets of patients. The incorporation of methods that allow for data collection outside of traditional study visits at academic centers, called remote decentralized trial design, is a growing trend that may increase diversity in study participation and allow for enhanced resiliency during the COVID-19 pandemic. Finally, reaching the goals of precision medicine in asthma will require increased emphasis on effectiveness studies. Recent advances in real-world data utilization from electronic health records are also discussed with a view toward pragmatic trial designs that could also incorporate the evaluation of biomarker signatures. Keywords Phenotypes Endotypes Longitudinal analysis Cohort Lung function Biomarkers Risk estimate Placebo-controlled trials Exacerbation Intervention Stratification


  • Development and Dynamic Responsiveness of the Acute Asthma Exacerbation Survey in Patients With Moderate to Severe Disease

    by Scott A. Laurenzo, Elizabeth A. Townsend, Nicole M. Lane Starr, Lori J. Wollet, Mario Castro, Nizar N. Jarjour, Christine A. Sorkness, Kristine E. Lee, Loren C. Denlinger


  • Widespread Air Trapping in Asthma Is Associated With Airway Eosinophilia and Altered Airway Behavior During Expiration

    by C. Leung, B. Huang, M. Castro, S.B. Fain, E.A. Hoffman, J. Choi, D. Mauger, L.C. Denlinger, N.N. Jarjour, E. Israel, et al.